Breast cancer prognostication and prediction in the postgenomic era

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1293-1306

  Lønning, Per P ^a,b   Knappskog, S ^a   Staalesen, V ^a   Chrisanthar, R ^a   Lillehaug, J R ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Microarray; Mutation; Prediction; Splicing; Therapy resistance

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARMUSTINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FANCONI ANEMIA PROTEIN; FLUOROURACIL; MITOMYCIN C; PROTEIN MDM2; PROTEIN P53; TAXANE DERIVATIVE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ALTERNATIVE RNA SPLICING; BREAST CANCER; CARCINOGENESIS; DNA REPAIR; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EPIGENETICS; GENE AMPLIFICATION; GENE SILENCING; GENETIC DISORDER; HUMAN; IN VIVO STUDY; MICROARRAY ANALYSIS; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOMATIC MUTATION; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS;

EID: 34548161624     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm013     Document Type: Review

References (164)

1. Johnson JM, Castle J, Garrett-Engele P et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003; 302 (5653): 2141-2144.
2. Lee C, Roy M. Analysis of alternative splicing with microarrays: successes and challenges. Gene Biol 2004; 5 (7).
3. Chen S, Ye JJ, Kijima I et al. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol 2005; 95 (1-5): 17-23.
4. Cawley S, Bekiranov S, Ng HH et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004; 116 (4): 499-509.
5. Bieda M, Xu XQ, Singer MA et al. Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Res 2006; 16 (5): 595-605.
6. Kannan K, Amariglio N, Rechavi G et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001; 20 (18): 2225-2234.
7. Yoon H, Liyanarachchi S, Wright FA et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 Proc Natl Acad Sci USA 2002; 99 (24): 15632-15637.
8. Lønning PE. Study of suboptimum treatment response: Lessons from breast cancer. Lancet Oncol 2003; 4: 177-185.
9. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365 (9472): 1687-1717.
10. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339: 1-15.
11. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339: 71-85.
12. Fisher B, Bauer M, Wickerham DL et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983; 52: 1551-1557.
13. Hartveit F, Thoresen S, Thorsen T, Tangen M. Histological grade and efferent vascular invasion in human breast carcinoma. Br J Cancer 1981; 44: 81-83.
14. Black MM, Barclay HC, Hankey BF. Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer 1975; 36: 2048-2055.
15. Rosen PP, Saigo PE, Braun DW et al. Predictors of recurrence in stage I breast carcinoma. Ann Surg 1981; 193 (1): 15-25.
16. McGurrin JF, Doria MI, Dawson PJ et al. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 1987; 59: 1744-1750.
17. Olszewski W, Darzynkiewicz Z, Rosen PP. Flow cytometry of breast carcinoma: 1. Relation of DNA ploidy level to histology and estrogen receptor. Cancer 1981; 48: 980-984.
18. Olszewski W, Darzynkiewicz Z, Rosen PP et al. Flow cytometry of breast carcinoma: II. Relation of tumor cell cycle distribution to histology and estrogen receptor. Cancer 1981; 48: 985-988.
19. McDivitt RW, Stone KR, Craig RB et al. A proposed classification of breast cancer based on kinetic information. Cancer 1986; 57: 269-276.
20. Hedley DW, Rugg CA, Gelber RD. Association of DNA index and s-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987; 47: 4729-4735.
21. Davis BW, Gelber RD, Goldhirsch A et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986; 58: 2662-2670.
22. Di Stefano D, Mingazzini PL, Scucchi L et al. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-6 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer 1991; 67: 463-471.
23. Olivier M, Langerod A, Carrieri P et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12 (4): 1157-1167.
24. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 233-240.
25. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
26. Aas T, Børresen A-L, Geisler S et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-814.
27. Kandioler-Eckersberger D, Ludwig C, Rudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-56.
28. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354 (20): 2103-2111.
29. Vollenweider-Zerargui L, Barrelet L, Wong Y et al. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 1986; 57: 1171-1180.
30. Hähnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979; 44 (2): 671-675.
31. Press MF, Bernstein L, Sauter G et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. Breast Cancer Res Treat 2005; 94: S54 (Abstr 1045).
32. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC (R) TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94: S5 (Abstr 1).
33. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23 (30): 7483-7490.
34. Tanner M, Isola J, Wiklund T et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/ neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24 (16): 2428-2436.
35. Lønning PE. Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance. Trends Mol Med 2004; 10: 113-118.
36. Cummings J, Anderson L, Willmott N, Smyth JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 1991; 27 (5): 532-535.
37. Speth P, van Hoesel Q, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15-31.
38. Muller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity [review]. Int J Mol Med 1998; 1 (2): 491-494.
39. Cummings J, Smyth JF. DNA topoisomerase-1 and topoisomerase-2 as targets for rational design of new anticancer drugs. Ann Oncol 1993; 4 (7): 533-543.
40. Muss HB, Thor AD, Berry DA et al. c-erB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330 (18): 1260-1266.
41. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15 (5): 537-547.
42. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8 (5): 1107-1116.
43. Jarvinen TAH, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156 (3): 839-847.
44. Paik SM, Bryant J, Park CH et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90 (18): 1361-1370.
45. Adenis A, Bonneterre J, Bonneterre ME et al. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial. J Clin Oncol 2001; 19 (3): 602-611.
46. Taubert H, Meye A, Wurl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 1996; 56 (18): 4134-4136.
47. Børresen-Dale A-L, Lothe RA, Meling GI et al. TP53 and long term prognosis in colorectal cancer; mutations in the L3 Zn-binding domain predict poor survival. Clin Cancer Res 1998; (4): 203-210.
48. deAnta JM, Jassem E, Rosell R et al. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: Null mutations are associated with poor prognosis. Oncogene 1997; 15 (24): 2951-2958.
49. Dong Y, Walsh MD, McGuckin MA et al. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 1997; 74 (4): 407-415.
50. Lens D, Dyer MJS, GarciaMarco JM et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997; 99 (4): 848-857.
51. Thorlacius S, Börresen AL, Eyfjörd JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 1993; 53: 1637-1641.
52. Bergh J, Norberg T, Sjögren S et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-1034.
53. Berns EMJJ, vanStaveren IL, Look MP et al. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 1998; 77 (7): 1130-1136.
54. Børresen AL, Andersen TI, Eyfjörd JE et al. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995; 14: 71-75.
55. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55 (1): 96-107.
56. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1 (14): 1017-1026.
57. Dowell SP, Wilson POG, Derias NW et al. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54 (11): 2914-2918.
58. Sjögren S, Inganäs M, Norberg T et al. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88 (3/4): 173-182.
59. Geisler S, Lønning PE, Aas T et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61 (6): 2505-2512.
60. Soong R, Robbins PD, Dix BR et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27 (10): 1050-1055.
61. Lavin MF, Scott S, Gueven N et al. Functional consequences of sequence alterations in the ATM gene. DNA Repair 2004; 3 (8-9): 1197-1205.
62. Lee SB, Kim SH, Bell DW et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001; 61 (22): 8062-8067.
63. Hupp TR. Regulation of p53 protein function through alterations in protein-folding pathways. Cell Mol Life Sci 1999; 55 (1): 88-95.
64. Gualberto A, Aldape K, Kozakiewicz K. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 1998; 95 (9): 5166-5171.
65. Danks MK, Whipple DO, McPake CR et al. Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines. Cell Death Differ 1998; 5 (8): 678-686.
66. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9 (5): 1595-1602.
67. Lønning P, Johnsen H, Geisler S et al. TP53 as a predictor of response to chemotherapy in breast cancer. ESO Sci Updat 1999; 4: 73-88.
68. Geisler S, Børresen-Dale A-L, Johnsen H et al. TP53 gene mutations predict the response to neoadjuvant treatment with FUMI in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-5588.
69. Diccianni MB, Yu J, Hsiao M et al. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994; 84: 3105-3112.
70. Wattel E, Preudhomme C, Hecquet B et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
71. Preudhomme C, Dervite I, Wattel E et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases. J Clin Oncol 1995; 13: 812-820.
72. Ichikawa A, Kinoshita T, Watanabe T et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-534.
73. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H et al. Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol 2000; 18: 4053-4059.
74. Moller P, Borg A, Evans DG et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101 (6): 555-559.
75. Robson ME, Chappuis PO, Satagopan J et al. A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2003; 6 (1): R8-R17.
76. Verhoog LC, Berns EMJJ, Brekelmans CTM et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 2000; 18 (21): 119S-124S.
77. Hedenfalk I, Duggan D, Chen YD et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344 (8): 539-548.
78. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95 (19): 1482-1485.
79. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98 (19): 10869-10874.
80. Sørlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100 (14): 8418-8423.
81. Egawa C, Motomura K, Miyoshi Y et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003; 78 (1): 45-50.
82. Egawa C, Miyoshi Y, Takamura Y et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001; 95 (4): 255-259.
83. D'Andrea AD, Grompe M. The Fanconi anaemia BRCA pathway. Nat Rev Cancer 2003; 3 (1): 23-34.
84. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9 (5): 568-574.
85. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995; 5 (3): 382-395.
86. Friedberg EC. How nucleotide excision repair protects against cancer. Nature Rev Cancer 2001; 1 (1): 22-33.
87. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629-656.
88. Chen SN, Wang WY, Lee S et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296 (12): 1479-1487.
89. Balmana J, Stockwell DH, Steyerberg EW et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006; 296 (12): 1469-1478.
90. Diep CB, Thorstensen L, Meling GI et al. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 2003; 21 (5): 820-829.
91. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (3): 247-257.
92. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamineplatinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59 (16): 3968-3971.
93. Dabholkar M, Bostick-Bruton F, Weber C et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84 (19): 1512-1517.
94. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16 (1): 309-316.
95. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4 (4): 296-307.
96. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343 (19): 1350-1354.
97. Hegi ME, Diserens A, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352 (10): 997-1003.
98. Paz MF, Yaya-Tur R, Rojas-Marcos I et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10 (15): 4933-4938.
99. Zhang YW, Newcomb PA, Egan KM et al. Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15 (2): 353-358.
100. Talseth BA, Meldrum C, Suchy J et al. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer 2006; 118 (10): 2479-2484.
101. Varley JM, McGown G, Thorncroft M et al. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 1997; 57 (15): 3245-3252.
102. Lohmann DR. RB1 gene mutations in retinoblastoma. Hum Mutat 1999; 14: 283-288.
103. Goldstein AM, Chan M, Harland M et al High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66 (20): 9818-9828.
104. Yip YL, Zoete V, Scheib H, Michielin O. Structural assessment of single amino acid mutations: Application to TP53 function. Hum Mutat 2006; 27 (9): 926-937.
105. Newman B, Millikan RC, King M-C Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev 1997; 19 (1): 69-79.
106. Eldering E, Spek CA, Aberson HL et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31 (23): E153.
107. Hogervorst FBL, Nederlof PM, Gille JJP et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003; 63 (7): 1449-1453.
108. Nygren AO, Ameziane N, Duarte HM et al. Methylation-specific MLPA (MS-MLPA): Simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005; 33 (14): E128.
109. Schouten JP, McElgunn CJ, Waaijer R et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30 (12) Art No e57, 2002.
110. Knappskog S, Geisler J, Arnesen T et al. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes Chromosomes Cancer 2006; 45 (12): 1155-1163.
111. Harland M, Taylor CF, Chambers PA et al. A mutation hotspot at the p14ARF splice site. Oncogene 2005; 24 (28): 4604-4608.
112. Harland M, Mistry S, Bishop DT, Bishop JAN. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 2001; 10 (23): 2679-2686.
113. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119 (5): 591-602.
114. De Gobbi M, Viprakasit V, Hughes JR et al. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 2006; 312 (5777): 1215-1217.
115. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6 (5): 386-398.
116. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006; 28 (4): 378-386.
117. Hirao A, Kong YY, Matsuoka S et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000; 287 (5459): 1824-1827.
118. Bartel F, Taubert H, Harris L. Alternative and aberrant splicing of MDM2mRNA in human cancer. Cancer Cell 2002; 2: 9-15.
119. Staalesen V, Falck J, Geisler S et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004; 23 (52): 8535-8544.
120. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994; 8 (15): 1739-1749.
121. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13 (6): 962-972.
122. Bourdon JC, Fernandes K, Murray-Zmijewski F et al p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19 (18): 2122-2137.
123. Concin N, Hofstetter G, Berger A et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: Evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005; 11 (23): 8372-8383.
124. Marx J. Debate surges over the origins of genomic defects in cancer. Science 2002; 297 (5581): 544-546.
125. Duesberg P, Li R, Fabarius A, Hehlmann R. The chromosomal basis of cancer. Cell Oncol 2005; 27 (5-6): 293-318.
126. McCann AH, Kirley A, Carney DN et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995; 71: 981-985.
127. Vos CBJ, TerHaar NT, Peterse JL et al. Cyclin D-1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 1999; 187 (3): 279-284.
128. Schraml P, Bucher C, Bissig H et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200 (3): 375-382.
129. Pollack JR, Sorlie T, Perou CM et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002; 99 (20): 12963-12968.
130. Laurie NA, Donovan SL, Shih CS et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444 (7115): 61-66.
131. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 (Suppl): 245-254.
132. Serman A, Vlahovic M, Serman L, Bulic-Jakus F. DNA methylation as a regulatory mechanism for gene expression in mammals. Coll Antropol 2006; 30 (3): 665-671.
133. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102 (30): 10604-10609.
134. Ushijima T. Innovation - detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5 (3): 223-231.
135. Zhu P, Huber E, Kiefer F, Gottlicher M. Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell Cycle 2004; 3 (10): 1240-1242.
136. Straume O, Smeds J, Kumar R et al. Significant impact of promoter hypermethylation and the 540 C > T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002; 161 (1): 229-237.
137. Hirsch CL, Bonham K. Histone deacetylase inhibitors regulate p21(WAF1) gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett 2004; 570 (1-3): 37-40.
138. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004; 112 (2): 171-178.
139. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
140. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100 (18): 10393-10398.
141. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11 (16): 5678-5685.
142. van't Veer L, Dal H, van de Vijver M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
143. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347 (25): 1999-2009.
144. Smid M, Wang YX, Klijn JGM et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24 (15): 2261-2267.
145. Ein-Dor L, Kela I, Getz G et al. Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 2005; 21 (2): 171-178.
146. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365 (9460): 671-679.
147. Chang J, Wooten E, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
148. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23 (3): 422-431.
149. Hannemann J, Oosterkamp HM, Bosch CAJ et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23 (15): 3331-3342.
150. Sørlie T, Perou CM, Fan C et al. Differential sensitivity to doxorubicin and mitomycin among breast cancers belonging to the intrinsic subtypes identified by gene expression profiling. Mol Cancer Ther 2006; 5: 2914-2918.
151. Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22 (12): 2284-2293.
152. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23 (29): 7265-7277.
153. Dressman HK, Hans C, Bild A et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006; 12 (3): 819-826.
154. Thuerigen O, Schneeweiss A, Toedt G et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24 (12): 1839-1845.
155. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 (23): 3726-3734.
156. Schmitt CA, Fridman JS, Yang M et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109 (3): 335-346.
157. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
158. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
159. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 1992; 69: 2603-2609.
160. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92 (16): 1295-1302.
161. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89 (13): 917-931.
162. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006; 7 (7): 861-879.
163. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12 (11): 1294-1300.
164. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006; 103 (15): 5923-5928.